Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Renown Regional Medical Center | OTHER |
Not provided
Not provided
Not provided
This study will assess the efficacy of oral vancomycin prophylaxis in preventing recurrent Clostridium difficile infection in hospitalized patients requiring oral or intravenous antibiotics for a suspected or confirmed bacterial infection.
This study will assess the efficacy of oral vancomycin prophylaxis in preventing recurrent Clostridium difficile infection in hospitalized patients requiring oral or intravenous antibiotics for a suspected or confirmed bacterial infection.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| No oral vancomycin | No Intervention | ||
| Oral vancomycin 125 mg twice daily | Experimental |
| |
| Oral vancomycin 125 mg daily | Experimental |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Oral Vancomycin | Drug | Oral vancomycin will be given concurrently with antibiotics to hospitalized patients with a history of Clostridium difficile infection to prevent recurrence |
| Measure | Description | Time Frame |
|---|---|---|
| Recurrent Clostridium difficile infection | Diarrheal illness, with at least 3 episodes of watery diarrhea over a 24 hour period and a positive toxin analysis or a positive PCR for Cdiff | During hospitalization or the 12 weeks after therapy |
| Measure | Description | Time Frame |
|---|---|---|
| Recurrence rate of CDI according to C diff inducing properties of the prescribed antibiotics |
|
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Lauren Zion, PharmD | Renown Regional Medical Center | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Renown Regional Medical Center | Reno | Nevada | 89502 | United States |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D003015 | Clostridium Infections |
| ID | Term |
|---|---|
| D016908 | Gram-Positive Bacterial Infections |
| D001424 | Bacterial Infections |
| D001423 | Bacterial Infections and Mycoses |
| D007239 | Infections |
Not provided
Not provided
| ID | Term |
|---|---|
| D014640 | Vancomycin |
| ID | Term |
|---|---|
| D006020 | Glycopeptides |
| D006001 | Glycoconjugates |
| D002241 | Carbohydrates |
| D010455 | Peptides |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| During hospitalization or the 12 weeks after therapy |
| Time between recurrent CDI and the last C diff infection | During hospitalization or the 12 weeks after therapy |
| Rate of recurrence of CDI in immunocompromised patients | HIV, Organ Transplantation, Current Immunosuppressive therapy, Hypogammaglobulinemia or steroids dose more than prednisone 20mg/day for 3 weeks | During hospitalization or the 12 weeks after therapy |
| Rate of recurrence of CDI in patients with a history of the NAP-1 strain | During hospitalization or the 12 weeks after therapy |
| Rate of reported adverse events | During hospitalization or the 12 weeks after therapy |
| Mortality rate | During hospitalization or the 12 weeks after therapy |
| D000602 |
| Amino Acids, Peptides, and Proteins |